Takeda Pharmaceutical (NYSE:TAK) Hits New 52-Week High – Here’s Why

Takeda Pharmaceutical Co. (NYSE:TAK) hit a new 52-week high during trading on Thursday. The stock traded as high as $21.48 and last traded at $21.5780, with a volume of 8,201 shares trading hands. The stock had previously closed at $21.06.

Analyst Ratings Changes

TAK has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 30th. Finally, Weiss Ratings raised Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy”.

Takeda Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 0.56, a current ratio of 1.15 and a quick ratio of 0.60. The company has a market capitalization of $69.34 billion, a PE ratio of 28.40 and a beta of -0.02. The stock has a 50-day simple moving average of $19.01 and a 200 day simple moving average of $17.62.

Insider Buying and Selling at Takeda Pharmaceutical

In other Takeda Pharmaceutical news, CEO Julie Kim sold 89,090 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $1,523,439.00. Following the completion of the transaction, the chief executive officer directly owned 391,489 shares in the company, valued at approximately $6,694,461.90. This trade represents a 18.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Anne Furney sold 30,868 shares of Takeda Pharmaceutical stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $527,842.80. Following the transaction, the general counsel owned 204,298 shares of the company’s stock, valued at approximately $3,493,495.80. The trade was a 13.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 627,457 shares of company stock worth $10,981,175. Insiders own 0.04% of the company’s stock.

Institutional Trading of Takeda Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of the business. Keybank National Association OH increased its stake in shares of Takeda Pharmaceutical by 75.5% during the 3rd quarter. Keybank National Association OH now owns 48,928 shares of the company’s stock worth $890,000 after purchasing an additional 21,044 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Takeda Pharmaceutical by 11.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 38,784 shares of the company’s stock worth $690,000 after purchasing an additional 4,035 shares during the last quarter. Point Nemo Capital LLC acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $1,453,000. Ethic Inc. lifted its stake in Takeda Pharmaceutical by 19.5% in the 3rd quarter. Ethic Inc. now owns 436,514 shares of the company’s stock valued at $7,940,000 after buying an additional 71,261 shares in the last quarter. Finally, May Hill Capital LLC purchased a new stake in Takeda Pharmaceutical in the 3rd quarter valued at approximately $256,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Tokyo, Japan. The company researches, develops, manufactures and commercializes medicines for patients worldwide, with a focus on areas of significant unmet medical need. Its principal therapeutic areas include gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines.

Takeda’s portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, and medicines for certain blood cancers and rare conditions.